We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05429762
Title Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT)
Acronym TusaRav-QT
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sanofi
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | TUR | FRA | ESP | BEL

Facility Status City State Zip Country Details
Mary Crowley Cancer Research Center Site Number : 8400002 Dallas Texas 75230 United States Details
Investigational Site Number : 0560001 Edegem 2650 Belgium Details
Investigational Site Number : 2500001 Dijon 21079 France Details
Investigational Site Number : 2500002 Marseille 13385 France Details
Investigational Site Number : 7240002 Barcelona Catalunya [Cataluña] 08023 Spain Details
Investigational Site Number : 7240001 Madrid Madrid, Comunidad De 28040 Spain Details
Investigational Site Number : 7920001 Ankara 06800 Turkey Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field